VERV vs. APGE, IRON, BHC, BEAM, ARQT, BHVN, SDGR, EWTX, JANX, and ETNB
Should you be buying Verve Therapeutics stock or one of its competitors? The main competitors of Verve Therapeutics include Apogee Therapeutics (APGE), Disc Medicine (IRON), Bausch Health Companies (BHC), Beam Therapeutics (BEAM), Arcutis Biotherapeutics (ARQT), Biohaven (BHVN), Schrödinger (SDGR), Edgewise Therapeutics (EWTX), Janux Therapeutics (JANX), and 89bio (ETNB). These companies are all part of the "pharmaceutical products" industry.
Verve Therapeutics vs.
Verve Therapeutics (NASDAQ:VERV) and Apogee Therapeutics (NASDAQ:APGE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.
Apogee Therapeutics has lower revenue, but higher earnings than Verve Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Verve Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Verve Therapeutics had 2 more articles in the media than Apogee Therapeutics. MarketBeat recorded 6 mentions for Verve Therapeutics and 4 mentions for Apogee Therapeutics. Verve Therapeutics' average media sentiment score of 0.86 beat Apogee Therapeutics' score of 0.22 indicating that Verve Therapeutics is being referred to more favorably in the media.
Verve Therapeutics has a beta of 1.67, meaning that its share price is 67% more volatile than the S&P 500. Comparatively, Apogee Therapeutics has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500.
Apogee Therapeutics has a net margin of 0.00% compared to Verve Therapeutics' net margin of -807.65%. Apogee Therapeutics' return on equity of -21.81% beat Verve Therapeutics' return on equity.
97.1% of Verve Therapeutics shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 19.9% of Verve Therapeutics shares are held by company insiders. Comparatively, 42.8% of Apogee Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Verve Therapeutics received 5 more outperform votes than Apogee Therapeutics when rated by MarketBeat users. However, 96.55% of users gave Apogee Therapeutics an outperform vote while only 60.00% of users gave Verve Therapeutics an outperform vote.
Verve Therapeutics currently has a consensus target price of $25.75, indicating a potential upside of 302.97%. Apogee Therapeutics has a consensus target price of $94.60, indicating a potential upside of 125.13%. Given Verve Therapeutics' higher probable upside, analysts plainly believe Verve Therapeutics is more favorable than Apogee Therapeutics.
Summary
Verve Therapeutics beats Apogee Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Verve Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VERV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Verve Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:VERV) was last updated on 6/11/2025 by MarketBeat.com Staff
Buy VERV Stock Free VERV Stock Alerts